About mindmaze therapeutics holding sa - RLFTF
MindMaze Therapeutics Holding SA engages in the development of AI-powered neurotherapeutics and pharmacological treatments for brain disorders. It focuses on addressing neurological and neuropsychiatric conditions through advanced research, clinical development, and technology-driven solutions. The company is headquartered in Geneva, Switzerland.
RLFTF At a Glance
Mindmaze Therapeutics Holding SA
Avenue de Sécheron 15
Geneva, Geneve (Geneva) 1202
| Phone | 41-21-552-08-01 | Revenue | 9.56M | |
| Industry | Miscellaneous Commercial Services | Net Income | -19,438,662.93 | |
| Sector | Commercial Services | 2024 Sales Growth | 42.365% | |
| Fiscal Year-end | 12 / 2025 | Employees | 31 | |
| View SEC Filings |
RLFTF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 6.095 |
| Price to Book Ratio | 1.44 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -7.583 |
| Enterprise Value to Sales | 4.602 |
| Total Debt to Enterprise Value | 0.054 |
RLFTF Efficiency
| Revenue/Employee | 308,307.174 |
| Income Per Employee | -627,053.643 |
| Receivables Turnover | 4.269 |
| Total Asset Turnover | 0.128 |
RLFTF Liquidity
| Current Ratio | 3.689 |
| Quick Ratio | 3.48 |
| Cash Ratio | 3.027 |
RLFTF Profitability
| Gross Margin | -32.066 |
| Operating Margin | -91.113 |
| Pretax Margin | -229.963 |
| Net Margin | -203.386 |
| Return on Assets | -26.006 |
| Return on Equity | -37.925 |
| Return on Total Capital | -45.395 |
| Return on Invested Capital | -36.39 |
RLFTF Capital Structure
| Total Debt to Total Equity | 5.845 |
| Total Debt to Total Capital | 5.522 |
| Total Debt to Total Assets | 4.026 |
| Long-Term Debt to Equity | 4.536 |
| Long-Term Debt to Total Capital | 4.285 |